“`html
{
"@context": "https://schema.org",
"@type": "FAQPage",
"mainEntity":[
{
"@type": "Question",
"name": "What were the major cardiology FDA approvals in Q2 2025?",
"acceptedAnswer": {
"@type": "Answer",
"text": "The FDA approved Widaplik (GMRx2), a triple combination drug for hypertension, and accepted the NDA submission for oral semaglutide 25 mg for chronic weight management. Additionally, Verve Therapeutics' VERVE-102 gene therapy received Fast Track designation."
}
},
{
"@type": "Question",
"name": "What were the key findings from cardiology clinical trials in Q2 2025?",
"acceptedAnswer": {
"@type": "Answer",
"text": "The HYPERION trial showed that sotatercept-csrk substantially reduced clinical worsening in pulmonary arterial hypertension (PAH) patients. Though, the ACHIEVE trial indicated that spironolactone did not significantly reduce cardiovascular risk in dialysis patients."
}
},
{
"@type": "Question",
"name": "What is VERVE-102 and what is it's role in treating high cholesterol?",
"acceptedAnswer": {
"@type": "Answer",
"text": "VERVE-102 is a gene editing medicine developed by Verve Therapeutics. It aims to lower LDL-C levels in individuals with hyperlipidemia and high cardiovascular risk through a single infusion, achieving significant reductions in LDL-C."
}
},
{
"@type": "Question",
"name": "What is Widaplik and how does it help in treating hypertension?",
"acceptedAnswer": {
